BRIEF published on 10/30/2025 at 21:05, 4 months 22 days ago TME Pharma's Semi-Annual Report and Financial Restructuring Financial Results Biotechnology CEO Appointment Bond Issuance TME Pharma
PRESS RELEASE published on 10/30/2025 at 21:00, 4 months 22 days ago TME Pharma publishes its semi annual results and half-year report TME Pharma publishes semi annual results and half-year report showing cost reductions, new CEO, and fundraising activities. Focus on NOX-A12 and NOX-E36 assets Fundraising Cost Reductions TME Pharma NOX-A12 Semi Annual Results
PRESS RELEASE published on 09/01/2025 at 08:45, 6 months 20 days ago Inside Information: Other news releases TME Pharma completes August financing, with €500k cash received on August 28th, bringing cash position to €2.35M. Organization aims to attract financing for cancer and eye therapies Cash Position TME Pharma August Financing Cost-efficient Organization Novel Therapies
BRIEF published on 09/01/2025 at 08:45, 6 months 20 days ago TME Pharma successfully completes its August fundraising round Biotechnology Fundraising Treasury Cryptocurrencies Cancer
BRIEF published on 08/25/2025 at 08:05, 6 months 27 days ago TME Pharma Secures €500,000 through New Bond Issue Investment Strategy Cost Reduction Bond Issuance Financial Strategy Shareholder Commitments
PRESS RELEASE published on 08/25/2025 at 08:00, 6 months 27 days ago Inside Information / Other news releases TME Pharma to raise €500k through bond issue & receives new shareholding notice. CEO & Chairman also invest. Funds to boost financial position & support R&D projects & investment strategy Fundraising Shareholding CEO Bond Issue TME Pharma
BRIEF published on 07/08/2025 at 08:05, 8 months 13 days ago TME Pharma Terminates Liquidity Contract Amid Cost Optimization Liquidity Contract Biotechnology Refinancing Cost Optimization TME Pharma
PRESS RELEASE published on 07/08/2025 at 08:00, 8 months 13 days ago Inside Information / Other news releases TME Pharma terminates liquidity contract with Invest Securities to optimize costs. Improve trading volume of shares and healthy liquidity deemed contract unnecessary. Finds success in refinancing and reducing operational costs Liquidity Contract Cost Optimization Trading Volume Organizational Restructuring TME Pharma
BRIEF published on 05/21/2025 at 08:05, 10 months ago TME Pharma Enhances Financial Outlook with €1.7M Bond Commitments Strategic Partnerships Bond Issuance Clinical Programs Financial Visibility Cost Structure
PRESS RELEASE published on 05/21/2025 at 08:00, 10 months ago Inside Information / Other news releases TME Pharma extends financial visibility to May 2026 by securing €1.7M financing through regular bonds with attached warrants. CEO and board show strong commitment to company's success Clinical Programs TME Pharma Financial Visibility Regular Bonds Private Warrants
Published on 03/20/2026 at 13:30, 1 day 11 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 1 day 12 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/20/2026 at 22:45, 1 day 2 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 3 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 3 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 1 day 4 hours ago BRP Unveils the Winners of its 6th International Design Challenge
Published on 03/20/2026 at 20:05, 1 day 4 hours ago INVESTOR ALERT: Goeasy Ltd. Shareholder Class Action
Published on 03/20/2026 at 19:00, 1 day 6 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 1 day 6 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 16:57, 1 day 8 hours ago Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 2 days 7 hours ago Filing of the 2025 Universal Registration Document
